 Bionano Genomics, a pioneer of optical genome mapping solutions, has announced second quarter results that included 73 year-over-year revenue growth as well as a 24 increase in sales of its nanochannel array flowcells. The company also launched version 6.2 of its NxClinical software that includes integrated genomic scar analysis for homologous recombination deficiency. 